MapLight Therapeutics
MPLT
9.09
-0.27
-2.88%
MapLight Therapeutics
US · MPLT
#3723 by market cap
Listed 2025
9.09
-0.27
-2.88%
Live - 5344 symbols - heartbeat 246s ago
· 2026-10-08 10:00
Pre-market
9.06
-3.21%
After-hours
9.36
0.00%
Overnight
9.36
0.00%
- Market cap
- 505.18M
- P/E (TTM)i
- -1.80
- P/Bi
- 1.45
- EPSi
- -3.66
- Div yieldi
- 0.00%
- 52W posi
- 1%
Reader sentiment
Are you bullish or bearish on MPLT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 12.89, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 4 years
Key ratios & quality
- Altman Z-Scorei
- 12.89
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | 4.10M | 7.61M | 14.42M | 30.73M |
| Research & development | 27.14M | 49.68M | 68.52M | 138.35M |
| Operating profit | -31.25M | -57.28M | -82.95M | -169.08M |
| Pretax profit | -30.02M | -55.71M | -77.58M | -161.15M |
| Tax | -- | -- | -- | -- |
| Net profit | -30.02M | -55.71M | -77.58M | -161.15M |
| Basic EPS | -1 | -2 | -3 | -19 |
| Diluted EPS | -1.15 | -2.13 | -2.96 | -18.56 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 0 | -- | 0 | 0 | 0 | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 3.76M | 3.82M | 4.40M | 18.75M | 10.82M | 10.11M |
| Research & development | 19.79M | 26.85M | 27.09M | 64.62M | 53.68M | 53.44M |
| Operating profit | -23.54M | -30.66M | -31.50M | -83.38M | -64.50M | -63.55M |
| Pretax profit | -22.34M | -29.85M | -29.42M | -79.55M | -60.67M | -60.19M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -22.34M | -29.85M | -29.42M | -79.55M | -60.67M | -60.19M |
| Basic EPS | -1 | -1 | -1 | -2 | -1 | -1 |
| Diluted EPS | -0.54 | -0.72 | -0.71 | -2.47 | -1.34 | -1.32 |
Balance sheet
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total current assets | 32.03M | 83.60M | 114.60M | 324.67M |
| Cash & ST investments | 27.67M | 79.77M | 108.80M | 305.10M |
| Inventory | -- | -- | -- | -- |
| Total assets | 39.39M | 91.41M | 136.92M | 479.51M |
| Total current liabilities | 12.60M | 14.70M | 15.92M | 16.23M |
| Short-term debt | 348.00K | 495.00K | 778.00K | 891.00K |
| Long-term debt | -- | -- | -- | -- |
| Total liabilities | 18,519,000.00 | 20,127,000.00 | 21,721,000.00 | 21,140,000.00 |
| Total equity | 20.87M | 71.28M | 115.20M | 458.37M |
| Retained earnings | -66.08M | -121.79M | -199.37M | -360.52M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 98.26M | 73.20M | 245.31M | 324.67M | 327.23M | 318.79M |
| Cash & ST investments | 92.26M | 60.47M | 227.17M | 305.10M | 310.11M | 304.73M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 111.57M | 84.12M | 257.22M | 479.51M | 418.79M | 368.35M |
| Total current liabilities | 12.98M | 14.98M | 18.56M | 16.23M | 14.28M | 19.29M |
| Short-term debt | 805.00K | 833.00K | 862.00K | 891.00K | 920.00K | 1.23M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 18,572,000.00 | 20,356,000.00 | 23,706,000.00 | 21,140,000.00 | 18,954,000.00 | 20,049,000.00 |
| Total equity | 93.00M | 63.76M | 233.52M | 458.37M | 399.83M | 348.30M |
| Retained earnings | -221.71M | -251.55M | -280.97M | -360.52M | -421.19M | -481.38M |
Cash flow
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | -26.58M | -52.01M | -78.82M | -138.14M |
| Depreciation & amortization | 574.00K | 556.00K | 701.00K | 578.00K |
| Free cash flow | -27.32M | -52.47M | -79.59M | -138.61M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- |
| Ending cash balance | 27.90M | 80.00M | 38.46M | 46.94M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -25.55M | -33.97M | -31.79M | -46.83M | -51.18M | -44.87M |
| Depreciation & amortization | 166.00K | 136.00K | 136.00K | 140.00K | 162.00K | 147.00K |
| Free cash flow | -25.55M | -34.03M | -31.82M | -47.21M | -51.20M | -44.89M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 50.36M | 33.67M | 64.35M | 46.94M | 55.91M | 71.84M |
Returns & efficiency
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| ROE %i | -- | -- | -- | -121.74 |
| ROA %i | -76.20 | -85.18 | -67.96 | -52.29 |
| ROIC %i | -- | -- | -- | -120.29 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | 2.54 | 5.69 | 7.20 | 20.01 |
| Quick ratioi | 2.20 | 5.43 | 6.83 | 18.80 |
| Debt / assetsi | 15.92 | 6.48 | 4.81 | 1.21 |
| LT debt / equityi | -- | -- | -- | 1.07 |
| Interest coveragei | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -121.74 | -216.82 | -445.24 |
| ROA %i | -53.25 | -109.88 | -39.98 | -52.29 | -75.23 | -101.59 |
| ROIC %i | -- | -- | -- | -120.29 | -210.89 | -428.38 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 7.57 | 4.89 | 13.22 | 20.01 | 22.91 | 16.52 |
| Quick ratioi | 7.11 | 4.04 | 12.24 | 18.80 | 21.71 | 15.79 |
| Debt / assetsi | 5.73 | 7.38 | 2.33 | 1.21 | 1.34 | 0.54 |
| LT debt / equityi | -- | -- | -- | 1.07 | 1.17 | 0.22 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 10:00:31 · For reference only, not investment advice and not tailored to your situation.